US.DGX · Quest Diagnostics

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.164381335247147,
        "turnoverUsdM": 373.31561860187,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DGX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 217.2236,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 6.3,
      "take_profit_price": 247.7016,
      "target_multiplier": 1.9,
      "technical_strength": 1.7,
      "take_profit_percent": 6.8
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.328762670494294,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 79.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 55.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 24
  },
  "market": {
    "ma20": 212.653,
    "ma50": 203.2482,
    "close": 231.9,
    "prevClose": 227.86,
    "avgVolume20": 1103941,
    "volumeRatio": 1.46,
    "changePercent": 1.77
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 24,
    "details": {
      "ret_5d": 0.11672922084176052,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 24,
      "vcp_bonus": 0,
      "vol_ratio": 1.4756268705284916,
      "ret_points": 16,
      "vol_points": 4,
      "range_ratio": 1.1137646953089417,
      "volat_points": 0,
      "day_range_pct": 0.030120742997875875,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 79.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 74,
        "contribution": 3.7
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 3.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 24,
        "contribution": 3.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 21.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72.33,
        "contribution": 21.7
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 55.9,
    "details": [
      "基本面分析總分: 3.7/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 3.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 21.7/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.7,
      "資金流": 12.4,
      "市場環境": 3.6,
      "情緒分析": 6,
      "技術信號": 21.7,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.4,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 373.31561860187,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DGX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.164381335247147,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141022424,
                "url": "https://finnhub.io/api/news?id=2a746b052ddb5d5a1b7207bb340cb81ee9971e6fd2b6cc8765fd924445859355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...",
                "category": "company",
                "datetime": 1785039446,
                "headline": "Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks"
              },
              {
                "id": 141021084,
                "url": "https://finnhub.io/api/news?id=8b503bc07a82d85543b5b9c4f8159127ba37fbae2d480a66ee7fefc6770a3db1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price targets shifting into the US$245 to US$265 range for more bullish views and into the low US$230s for more cautious ones. These adjustments reflect how analysts are weighing the Q2 beat, higher full year guidance, and ongoing volume and margin debates when refreshing their models. Read on to see what is driving this evolving narrative and how you can...",
                "category": "company",
                "datetime": 1785024976,
                "headline": "Quest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher Guidance"
              },
              {
                "id": 141006631,
                "url": "https://finnhub.io/api/news?id=1c56ab7276b09cabb5ba57edf54c840ee29fe58faceb1690d18865a84cad7d25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1784898903,
                "headline": "Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?"
              },
              {
                "id": 140999744,
                "url": "https://finnhub.io/api/news?id=b9bc9961f77bf235b504e1c7436295e28b1b6c04e707aef97b20fb32164bb559",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.",
                "category": "company",
                "datetime": 1784840594,
                "headline": "Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ..."
              },
              {
                "id": 140996570,
                "url": "https://finnhub.io/api/news?id=12970ef12dd779191b05ff959d0e56dc8de0cb7991d045959f83629c2f728df3",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call July 23, 2026 8:30 AM EDTCompany ParticipantsDan Haemmerle - Interim VP of Investor Relations...",
                "category": "company",
                "datetime": 1784817036,
                "headline": "Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140995015,
                "url": "https://finnhub.io/api/news?id=9de845c41664579a27569b2fd50ad938c3d98553006d4592daa2f8d08c41cdd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.",
                "category": "company",
                "datetime": 1784813160,
                "headline": "DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised"
              },
              {
                "id": 140993611,
                "url": "https://finnhub.io/api/news?id=5b5cc5747c30c4437cda6501aeb6bbb7f8ea3888236804e6b7ccb0a97a359d06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 billion. Its non-GAAP profit of $3.12 per share was 10.5% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1784809175,
                "headline": "Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars"
              },
              {
                "id": 140993612,
                "url": "https://finnhub.io/api/news?id=296e1a4b81d3c30deeca48ff495e6484e8eac65900eddcf9f8186d81a195914c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) delivered earnings and revenue surprises of +11.03% and +2.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784808002,
                "headline": "Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates"
              }
            ],
            "raw_source": [
              {
                "id": 141037264,
                "url": "https://finnhub.io/api/news?id=5e8c27d54f44ab00e93e1e4403a1e169894de3217aaf47d51b3a36d29c6f24e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The company raised its outlook on booming AI demand, but the stock is telling a different story by standing still.",
                "category": "company",
                "datetime": 1785185769,
                "headline": "Equinix Stock Has A Message For Management"
              },
              {
                "id": 141029995,
                "url": "https://finnhub.io/api/news?id=cf95f748a926e675e4bca83137a81bef2476ef034cb3b876ef5e27d6384ad7b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Demand for medical testing services is rising.",
                "category": "company",
                "datetime": 1785118950,
                "headline": "Why Quest Diagnostics Stock Climbed This Past Week"
              },
              {
                "id": 141022424,
                "url": "https://finnhub.io/api/news?id=2a746b052ddb5d5a1b7207bb340cb81ee9971e6fd2b6cc8765fd924445859355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...",
                "category": "company",
                "datetime": 1785039446,
                "headline": "Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks"
              },
              {
                "id": 141021084,
                "url": "https://finnhub.io/api/news?id=8b503bc07a82d85543b5b9c4f8159127ba37fbae2d480a66ee7fefc6770a3db1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price targets shifting into the US$245 to US$265 range for more bullish views and into the low US$230s for more cautious ones. These adjustments reflect how analysts are weighing the Q2 beat, higher full year guidance, and ongoing volume and margin debates when refreshing their models. Read on to see what is driving this evolving narrative and how you can...",
                "category": "company",
                "datetime": 1785024976,
                "headline": "Quest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher Guidance"
              },
              {
                "id": 140843515,
                "url": "https://finnhub.io/api/news?id=410c2274a53e42f425299ba3ba6dd240ae075acddeb862ae7f347dfd8789675e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does CSX (CSX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784908803,
                "headline": "Are You Looking for a Top Momentum Pick? Why CSX (CSX) is a Great Choice"
              },
              {
                "id": 141019786,
                "url": "https://finnhub.io/api/news?id=608530e393c7a93c8dd6db84f3cbe8fcae8410e5fbef6d4402c71ff9a2a5f200",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Mizuho  analyst Ann Hynes   maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.",
                "category": "company",
                "datetime": 1784904099,
                "headline": "Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260"
              },
              {
                "id": 141019787,
                "url": "https://finnhub.io/api/news?id=41c0bd6b2f6001affdb1a796a27d3a2dc475918aea741a92403a50fb4c170034",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Truist Securities  analyst David Macdonald   maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.",
                "category": "company",
                "datetime": 1784902133,
                "headline": "Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250"
              },
              {
                "id": 141006631,
                "url": "https://finnhub.io/api/news?id=1c56ab7276b09cabb5ba57edf54c840ee29fe58faceb1690d18865a84cad7d25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1784898903,
                "headline": "Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?"
              },
              {
                "id": 141007264,
                "url": "https://finnhub.io/api/news?id=6259524bdc28aae7071c05f8528bf07868914612f2a7e90ed8bd98b3f7cbc92b",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Barclays  analyst Luke Sergott   maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.",
                "category": "company",
                "datetime": 1784891316,
                "headline": "Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250"
              },
              {
                "id": 141007265,
                "url": "https://finnhub.io/api/news?id=9f090ca50df5c43091ee39bcf08d10ddda08abef377de99955b9491dd800aca3",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Baird  analyst Eric Coldwell   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.",
                "category": "company",
                "datetime": 1784878397,
                "headline": "Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255"
              },
              {
                "id": 141003889,
                "url": "https://finnhub.io/api/news?id=fef3b5c95651e0fb5dce2ffb9e138695438f52f3324617220626e9d59ef41ef0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2271662218/image_2271662218.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a buy.",
                "category": "company",
                "datetime": 1784872751,
                "headline": "Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results"
              },
              {
                "id": 141004530,
                "url": "https://finnhub.io/api/news?id=94fe730858e71cd13e2de869655feef15613c319b30ce2cac2656e8bcfd9c24b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1784853056,
                "headline": "Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary"
              },
              {
                "id": 140999744,
                "url": "https://finnhub.io/api/news?id=b9bc9961f77bf235b504e1c7436295e28b1b6c04e707aef97b20fb32164bb559",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.",
                "category": "company",
                "datetime": 1784840594,
                "headline": "Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ..."
              },
              {
                "id": 140998125,
                "url": "https://finnhub.io/api/news?id=61e93e67bb00991cb136fac6b4056351dd5960de43ee30d10637a23b175e4933",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi",
                "category": "company",
                "datetime": 1784833645,
                "headline": "Quest Diagnostics Q2 Earnings Call Highlights"
              },
              {
                "id": 140997115,
                "url": "https://finnhub.io/api/news?id=2dc5c73f42c70ceb223c39789ca8fffdc01973a9abe48a2cfb8eb91f246ad1fc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1784833500,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140995778,
                "url": "https://finnhub.io/api/news?id=44e41ed78fcf0cbec34961ce765001922373f26b941224a650dc205af432bd18",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Thursday's session.",
                "category": "company",
                "datetime": 1784826300,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 140993990,
                "url": "https://finnhub.io/api/news?id=5206b71e1b095efb2af34273688ebb056f5dbbce6ba73d7fae75c33032ce9e3b",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1784817301,
                "headline": "Which S&P500 stocks are gapping on Thursday?"
              },
              {
                "id": 140996570,
                "url": "https://finnhub.io/api/news?id=12970ef12dd779191b05ff959d0e56dc8de0cb7991d045959f83629c2f728df3",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call July 23, 2026 8:30 AM EDTCompany ParticipantsDan Haemmerle - Interim VP of Investor Relations...",
                "category": "company",
                "datetime": 1784817036,
                "headline": "Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140995013,
                "url": "https://finnhub.io/api/news?id=1e6bd995dea22d9794db10c84b264a9cd1cadd544e6e313b6ec6da8608b4b2c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.",
                "category": "company",
                "datetime": 1784815753,
                "headline": "Quest Diagnostics Surges After Hims- And Oura-Tied Beat"
              },
              {
                "id": 140996337,
                "url": "https://finnhub.io/api/news?id=c96d2536df1001a49c88c925f609d2a4c10705b22d0643341c2e57b6f5206f11",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "2026-07-23. The following slide deck was published by Quest Diagnostics Incorporated in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1784815424,
                "headline": "Quest Diagnostics Incorporated 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 140999198,
                "url": "https://finnhub.io/api/news?id=46262a57bcf7521b80aec8636a36781da2a7773626eb8608b2bc737f88e7c283",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Alhambra--Ca--Usa---May-11--2022-Quest-D.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.",
                "category": "company",
                "datetime": 1784814435,
                "headline": "Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning"
              },
              {
                "id": 140995014,
                "url": "https://finnhub.io/api/news?id=2c2e9f2766e03bf47fb07a63724a406dcadaf9726c327246e7b641bab3bbba99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1784814003,
                "headline": "Are Medical Stocks Lagging  Corcept Therapeutics (CORT) This Year?"
              },
              {
                "id": 140995015,
                "url": "https://finnhub.io/api/news?id=9de845c41664579a27569b2fd50ad938c3d98553006d4592daa2f8d08c41cdd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.",
                "category": "company",
                "datetime": 1784813160,
                "headline": "DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised"
              },
              {
                "id": 140992858,
                "url": "https://finnhub.io/api/news?id=fc6e06457fb216266ed7ade2993afcedbedc6648f41f9685a003e7793ce61b00",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1784810101,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 140993611,
                "url": "https://finnhub.io/api/news?id=5b5cc5747c30c4437cda6501aeb6bbb7f8ea3888236804e6b7ccb0a97a359d06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 billion. Its non-GAAP profit of $3.12 per share was 10.5% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1784809175,
                "headline": "Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars"
              },
              {
                "id": 140993612,
                "url": "https://finnhub.io/api/news?id=296e1a4b81d3c30deeca48ff495e6484e8eac65900eddcf9f8186d81a195914c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) delivered earnings and revenue surprises of +11.03% and +2.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784808002,
                "headline": "Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 140992237,
                "url": "https://finnhub.io/api/news?id=3a572607295f1c2680ea74f0938dd8089c08f9eba18e387e94075521f919203b",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) smashed Q2 2026 expectations with EPS of $3.12 vs $2.85 estimate and revenue of $3.04B. Shares surged 6.7% on raised full-year guidance and strong operational performance.",
                "category": "company",
                "datetime": 1784805716,
                "headline": "Quest Diagnostics (NYSE:DGX) Surges After Crushing Q2 Estimates and Raising Guidance"
              },
              {
                "id": 140992646,
                "url": "https://finnhub.io/api/news?id=b95b6add565b0f75bba2cadd5ef4396a42c8376ab99768a04af7529cf4ea9a79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1784803500,
                "headline": "Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026"
              },
              {
                "id": 140993902,
                "url": "https://finnhub.io/api/news?id=7a5cfc6186cd9ffec5c304af7f0a23f3e13d78cfed2ff3b71b893a538836ec38",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/23/Orlando--Florida--Usa--February-8--2020-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd (GIBO), Novocure Ltd (NVCR), Cleveland-Cliffs Inc (CLF), Merlin Inc (MRLN), Medpace Holdings Inc (MEDP), Oatly Group AB (OTLY), Imax Corp (IMAX), United Rentals Inc (URI), Oceaneering International Inc (OII), and Quest Diagnostics Inc (DGX).",
                "category": "company",
                "datetime": 1784802041,
                "headline": "Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday"
              },
              {
                "id": 140999200,
                "url": "https://finnhub.io/api/news?id=2cd45c29a0c33b25a19031b0b9791519ab918e22a5e62c1eedb8616e31707f93",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.\nThis content is powered by Benzinga APIs.",
                "category": "company",
                "datetime": 1784799194,
                "headline": "Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call"
              },
              {
                "id": 140993809,
                "url": "https://finnhub.io/api/news?id=a47ad7f0bc8a271af3493561d9e532c43ff1705e233807236e6b2cf91a6dc883",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Companies Reporting Before The Bell\n• Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. \n• Dime Commercial (NYSE:DCOM) is expected to report",
                "category": "company",
                "datetime": 1784790711,
                "headline": "Earnings Scheduled For July 23, 2026"
              },
              {
                "id": 140999202,
                "url": "https://finnhub.io/api/news?id=f19d62624e8fd11b15ac5ae7f01eeaa4c6b85695c746a3caccd7647178cd7421",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 analyst estimate. Raises FY2026 sales outlook from $11.780 billion-$11.900 billion to $11.950 billion-$12.050",
                "category": "company",
                "datetime": 1784789270,
                "headline": "Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B Est"
              },
              {
                "id": 140999203,
                "url": "https://finnhub.io/api/news?id=805d19b4f4f7975d25c0a82c4a1c3f4b7cd01601a2413817edfc58bf7080774a",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..",
                "category": "company",
                "datetime": 1784789218,
                "headline": "Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est"
              },
              {
                "id": 140999204,
                "url": "https://finnhub.io/api/news?id=977277d853139c2bd2e58ac6099d0d05a222d984e737d9be0a65512e33b19f62",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst consensus estimate of $2.83 by 10.25 percent. This is a 19.08 percent increase over earnings of $2.62 per share from the",
                "category": "company",
                "datetime": 1784789185,
                "headline": "Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate"
              },
              {
                "id": 140969627,
                "url": "https://finnhub.io/api/news?id=4c5f5d84c5f21b37ba67458887dddbc1ebc9a066d2574ffc3e222d8be1dba7b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "FAST, GD, UNH, TXRH and DGX are five stocks that combine long records of uninterrupted payouts with stable earnings and solid cash flow.",
                "category": "company",
                "datetime": 1784631720,
                "headline": "5 High Dividend Yield Stocks to Buy for a Stable Portfolio in 2H 2026"
              },
              {
                "id": 140940379,
                "url": "https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.",
                "category": "company",
                "datetime": 1784329960,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"
              },
              {
                "id": 140898445,
                "url": "https://finnhub.io/api/news?id=8cce6b82d94a14e6f1c6129d038c9d068492f45c6095479b1ffc1aafdad7bbfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.",
                "category": "company",
                "datetime": 1784037480,
                "headline": "Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus"
              },
              {
                "id": 140898225,
                "url": "https://finnhub.io/api/news?id=b650bd0404d07d15723345af5bfd6859bfe7fe9df9d504ab0885e15a63cbfe95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.",
                "category": "company",
                "datetime": 1784036040,
                "headline": "Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?"
              },
              {
                "id": 140886479,
                "url": "https://finnhub.io/api/news?id=8d5d12187252ef0e8147e50d9c59ae99b9b436fe3ec1128d445997fa97f1f15a",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Baird  analyst Eric Coldwell   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.",
                "category": "company",
                "datetime": 1783929439,
                "headline": "Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236"
              },
              {
                "id": 140869905,
                "url": "https://finnhub.io/api/news?id=7c44cbdf232fd722d46c7c1836b6ff306d3c7cf5dce2f2dc1a99ca8db8c171f0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes the \"Best Dividend\" screen with a sustainable 1.59% yield, low 35% payout ratio, and strong profitability. A solid choice for reliable dividend income and growth.",
                "category": "company",
                "datetime": 1783763431,
                "headline": "Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability"
              },
              {
                "id": 140861842,
                "url": "https://finnhub.io/api/news?id=dea4a96367e9b1a7e12508fa236e7172cb3413edda8b934757bfbaf6b5228b7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025, an increase of nearly 46% compared to 13.1% in 2021, finds the 2026 Quest Diagnostics Drug Testing Index™. For more information, visit www.QuestDiagnostics.com/DTI.",
                "category": "company",
                "datetime": 1783689840,
                "headline": "One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns"
              },
              {
                "id": 140840711,
                "url": "https://finnhub.io/api/news?id=70f8fddaf6c1d9f28cfb731d0d184f3c03704f72b9b47c49b3aad0e44c40e3a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care soluti",
                "category": "company",
                "datetime": 1783515120,
                "headline": "Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI"
              },
              {
                "id": 140821261,
                "url": "https://finnhub.io/api/news?id=b7403286549b8549769139c3ef0d824ea7877567456fd904a8591fea24374fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Zacks highlights PDF Solutions, LifeStance Health and Paychex among stocks and portfolios that outperformed as markets weighed softer jobs data and earnings.",
                "category": "company",
                "datetime": 1783343700,
                "headline": "Beat the Market the Zacks Way: PDF Solutions, LifeStance Health, Paychex in Focus"
              },
              {
                "id": 140795133,
                "url": "https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.",
                "category": "company",
                "datetime": 1783015043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"
              },
              {
                "id": 140791609,
                "url": "https://finnhub.io/api/news?id=1163bcc6bf803bb433b2cba9b963d451d95a47f2b2b2a3bc11367cdfed6d0641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1782998102,
                "headline": "Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?"
              },
              {
                "id": 140784902,
                "url": "https://finnhub.io/api/news?id=9dfd63db8152d602bfa95049a98803d3a06a30879dfcd935c88a530be20311fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.",
                "category": "company",
                "datetime": 1782917204,
                "headline": "Quest Diagnostics's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140773035,
                "url": "https://finnhub.io/api/news?id=1a9df6d3e66681b87e33417a87fd52ba6bc6e255861fda7aeefb02e7c54e5838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1782826803,
                "headline": "Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140764106,
                "url": "https://finnhub.io/api/news?id=f4fbe12de44dd4368caac0162ec6b1a256f57d5dae0fc7960291663304ece869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato",
                "category": "company",
                "datetime": 1782754200,
                "headline": "Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140762661,
                "url": "https://finnhub.io/api/news?id=436a621c27ef4c5a4c8af1390e6ab512fb77305db81ffffa5d81207c83cb97fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "How Abbott's Largest Segment Is Preparing for the Next Growth Phase"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 49,
            "discarded_article_count": 38
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.7,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1051140,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1322450,
              "avg_vol_20": 1090935,
              "avg_vol_30": 1051140,
              "range_pct_10": 0.1586028528936116,
              "range_pct_20": 0.1586028528936116,
              "range_pct_30": 0.1938335573020076,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2581102422132162,
              "dist_to_20d_high": 0.024728782908570942,
              "down_shrink_days": 3,
              "breakout_level_20d": 237.78,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.8182424916573973
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.164381335247147,
              "turnoverUsdM": 373.31561860187,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DGX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 217.2236,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 6.3,
            "take_profit_price": 247.7016,
            "target_multiplier": 1.9,
            "technical_strength": 1.7,
            "take_profit_percent": 6.8
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.328762670494294,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.DGX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 7.3382,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.16
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 196.85
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0117
    },
    "kdj": {
      "d": 58.04,
      "j": 93.35,
      "k": 69.81,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 58.69
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 1071113,
      "recentSlope": 489931.3,
      "previousSlope": -588480
    },
    "rsi": 70.12,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 202.4565,
      "position": "SAR喺價下",
      "distancePct": 12.7,
      "previousTrend": "上升"
    },
    "ma50": 203.2482,
    "macd": {
      "macd": 5.491623794320191,
      "trend": "強烈看漲",
      "signal": 3.434150548553654,
      "histogram": 2.057473245766537
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 215.6807,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.46,
      "score": 6,
      "avgVolume": 1103941,
      "currentVolume": 1609813
    },
    "derived": {
      "ma20": 212.653,
      "ma50": 203.2482,
      "prevClose": 227.86,
      "avgVolume10": 1426541,
      "avgVolume20": 1103941,
      "changePercent": 1.77,
      "avgVolumeForScore": 1103941
    },
    "ma_cross": {
      "ma20": 212.653,
      "ma50": 203.2482,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 211.552,
      "prevMa50": 202.4272,
      "spreadPct": 4.63,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 197.186,
      "upper": 228.12,
      "position": "上半部"
    },
    "rsi_short": 86.61,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.46
    }
  }
}

{
  "close": 231.9,
  "volume": 1609813,
  "changePercent": 1.77
}